Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016809
Chunk: 19

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 19
---
     
 to be beneficially owned by: (i) Armistice Capital, LLC, or Armistice Capital, as the investment 
 manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice            
 Capital. The address of the Master Fund is c/o Armistice Capital, LLC, 510 Madison Ave, 7th      
 Floor, New York, NY 10022.                                                                       |

| (3) | The selling shareholder holds (i)                                                              
 warrants issued by us in prior transactions which entitle the selling shareholder to purchase  
 an aggregate of 458,300,000 Ordinary Shares (in the form of Depositary Shares), and (ii)       
 Series D Warrants which entitle the selling shareholder to purchase an aggregate of 9,600,000  
 Ordinary Shares (in the form of Depositary Shares), which we are registering hereby. The       
 warrants are subject to a beneficial ownership limitation of 9.99%, which does not permit      
 the selling shareholder to exercise that portion of the warrants that would result in the      
 selling shareholder and its affiliates owning, after exercise, a number of our Ordinary Shares 
 in excess of the beneficial ownership limitation. The amounts and percentages in the table     
 do not give effect to the 9.99% beneficial ownership limitation, if applicable. The principal  
 business address of Bigger Capital Fund, LP is 11700 West Charleston Blvd, #170-659, Las       
 Vegas, NV 89135.                                                                               |

| 14 |

| (4) | The selling shareholder holds (i)                                                                 
 warrants issued by us in prior transactions which entitle the selling shareholder to purchase     
 an aggregate of 89,400,000 Ordinary Shares (in the form of Depositary Shares), and (ii) Series    
 D Warrants which entitle the selling shareholder to purchase an aggregate of 3,200,000 Ordinary   
 Shares (in the form of Depositary Shares), which we are registering hereby. The warrants          
 are subject to a beneficial ownership limitation of 9.99%, which does not permit the selling      
 shareholder to exercise that portion of the warrants that would result in the selling shareholder 
 and its affiliates owning, after exercise, a number of our Ordinary Shares in excess of the       
 beneficial ownership limitation. The amounts and percentages in the table do not give effect      
 to the 9.99% beneficial ownership limitation, if applicable. Boothbay Absolute Return Strategies, 
 LP, a Delaware limited partnership, or BBARS,